In contrast, a significant pooled HR of 0.43 (95% CI,0.29–0.65; P < 0.001) was evident for progression-free survival in patients with high expressing MAD2 ovarian tumours compared to those with low expressing MAD2 tumours. The gene discussed is MAD2L1; the disease is neoplasm.